Related Experiment Video
Updated: May 25, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation
Patricija Lunar1, Hana Meglič1, Mateja Vehar2
1Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Insights
PCSK9 inhibitors significantly alter gene expression related to lipid regulation, inflammation, and coagulation in coronary artery disease patients. This suggests PCSK9i impacts atherosclerosis beyond just lowering lipids.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Pharmacogenomics
Background:
- Atherosclerosis involves inflammation and haemostasis.
- PCSK9 inhibitors (PCSK9i) are emerging atherosclerosis treatments.
- Investigating PCSK9i effects on gene expression in CAD patients.
Purpose of the Study:
- To assess PCSK9i influence on gene expression in CAD patients.
- To examine regulators of lipoprotein homeostasis, inflammation, and coagulation.
Main Methods:
- Quantitative polymerase chain reaction (qPCR) used for gene expression analysis.
- Studied genes: SREBP1, SREBP2, LDLR, LIPC, LRP8, CD36, CD63, CD14.
- Analysis included 96 CAD patients and 25 healthy controls.
Main Results:
- Significant differences in gene expression between CAD patients and healthy controls.
- PCSK9i treatment led to significant changes in all studied genes' expression.
- Gene expression alterations occurred in lipid regulators, inflammatory markers, and coagulation parameters.
Conclusions:
- PCSK9 inhibitors significantly affect gene expression of lipid regulators.
- PCSK9i also impact inflammatory markers and coagulation parameters.
- These effects appear independent of PCSK9i's lipolytic activity.
Background:
PCSK9 inhibitors (PCSK9i) represent a newer form of atherosclerosis treatment. Inflammation and haemostasis are key processes in the development of atherosclerosis. In this study, we investigated the influence of therapy with PCSK9i in patients with coronary artery disease (CAD) on regulators for lipoprotein homeostasis, inflammation and coagulation.
Methods:
Using quantitative polymerase chain reaction (qPCR), we measured the expression of the genes involved in lipoprotein homeostasis, namely for sterol regulatory element-binding protein 1 (SREBP1), SREBP2, low-density lipoprotein receptor (LDLR), hepatic lipase type C (LIPC), LDLR-related protein 8 (LRP8), and the genes associated with inflammation and coagulation, such as cluster of differentiation (CD) 36 (CD36), CD63, and CD14 in 96 patients with CAD and 25 healthy subjects.
Results:
Significant differences in the expression of the investigated genes between patients and healthy controls were found. Treatment with PCSK9i also resulted in significant changes in the expression of all studied genes.
Conclusions:
We established that PCSK9i may have a significant effect on the gene expression of lipid regulators, inflammatory markers, and coagulation parameters, independent of their lipolytic effect.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Inflammation
Cholesterol: Significance and Regulation
Considering cholesterol and...

